 |
市場調查報告書
商品編碼
1378619
CKD 的高血壓市場：按藥物類別、配銷通路和地區分類Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, Beta-Blockers, Calcium Channel Blockers, Others ), By Distribution Channel, By Geography |
||||||
預計到 2023 年，全球 CKD 高血壓市場價值將達到 2.542 億美元，並預計在預測期內（2023-2030 年）年複合成長率為 10.7%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2022年 | 2023年市場規模 | 2.542 億美元 |
| 實績資料 | 2018-2021 | 預測期 | 2023-2030 |
| 預測期年複合成長率 | 10.70% | 2030年市場規模預測 | 5.176 億美元 |
慢性腎臟病（CKD）是高血壓不受控制的常見原因和結果。高血壓和 CKD 之間的相互作用很複雜，會增加不良心腦血管結局的風險。 CKD 高血壓的病理學複雜，涉及多種因素，包括腎單位體積減少、鈉儲存和細胞外容量增加、交感神經系統過度活躍、腎素-血管收縮素-醛固酮系統等激素激活以及內皮功能障礙。涉及。慢性腎臟病(CKD) 患者的高血壓可以使用不同的藥物類別進行治療，包括利尿劑、RAS阻斷劑、Hui 阻斷劑和鈣通道拮抗。根據美國疾病管制與預防中心的數據，預計到 2022 年，超過七分之一的美國成年人，約 3,550 萬人（占美國人口的 14%）將患有 CKD。 CKD 盛行率的不斷上升正在推動對新藥和藥品的需求，主要企業都在積極努力增加研發活動和臨床試驗。
市場動態
主要企業都熱衷於合作研究，針對各種疾病進行臨床試驗。例如，2023年6月12日，全球製藥公司諾華公司（Novartis AG）收購了Chinook Therapeutics公司，這是一家臨床階段的生物技術公司，以創新藥物策略和腎臟管道收購。此外，預計主要企業增加產品推出將在預測期內推動市場成長。例如，2023年1月24日，總部位於德國的全球製藥公司勃林格殷格翰國際有限公司宣布美國食品藥物管理局（FDA）核准Jardiance的III期試驗。
本研究的主要特點
- 本報告詳細分析了全球 CKD 高血壓市場，並介紹了以 2022 年為基準年的預測期（2023-2030）的市場規模和復合年度(年複合成長率)。
- 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
- 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球 CKD 市場高血壓的主要企業。
- 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
- 全球 CKD 高血壓市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 透過用於分析 CKD 市場全球高血壓的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 調查目的和假設
- 這項研究的目的
- 假設
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章 市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 市場機會
- 影響分析
- 最近測試啟動
- 流行病學
- 合併、收購和合作
- 主要進展
- 管道分析
- 法規場景
- 主要進展
- 治療方法
- PEST分析
第4章 全球CKD高血壓市場－新型冠狀病毒感染疾病（COVID-19）的影響分析
- 經濟影響
- 新型冠狀病毒感染疾病（COVID-19）的流行病學
- 對需求和供給的影響
第5章 CKD 市場的全球高血壓，依藥物類別，2018-030
- 利尿劑
- RAS區塊
- Whi阻斷劑
- 鈣通道阻斷劑
- 其他（α-受體阻斷劑、血管擴張劑、蛋白尿等）
第6章 CKD 市場全球高血壓（依配銷通路），2018-2030
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 2018-2030 年全球 CKD 市場高血壓（按地區）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第8章 競爭形勢
- 公司簡介
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- CH Boehringer Sohn AG &Ko. KG Kissei Pharmaceutical Co., Ltd.
- KBP Biosciences Holdings Limited
- Ardelyx
- Reata Pharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd
- Pfizer Inc.
- Bayer Pharmaceuticals, Inc
- GSK plc.
第9章 章節
- 參考
- 調查方法
The Global Hypertension in CKD Market is estimated to be valued at US$ 254.2 Mn in 2023 and is expected to exhibit a CAGR of 10.7% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 254.2 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 10.70% | 2030 Value Projection: | US$ 517.6 Mn |
Chronic kidney disease (CKD) is a common cause of and a result of uncontrolled hypertension. The interaction between hypertension and CKD is complex and increases the risk of adverse cardiovascular and cerebrovascular outcomes. The pathophysiology of hypertension in CKD is complex, with multiple factors contributing, including decreased nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, hormone activation, including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Hypertension in Chronic Kidney Disease (CKD) patients is treated with drug classes such as diuretics, RAS blockade, β - blockers, calcium channel blockers. According to the Centre for Disease Control and Prevention, in 2022 more than 1 in 7 U.S. adults-about 35.5 Mn people, or 14% of the U.S. population are estimated to have CKD. Growing prevalence of CKD is increasing the demand for new drugs and medicines and Key players are actively involved in increasing their research and developmental activities and clinical trials, which are expected to bolster thw growth of Hypertension in CKD Market
Market Dynamics
The Key players are indulged in collaborating in order to conduct clinical trials for different diseases. For instance, on June 12, 2023, Novartis AG, a global pharmaceutical company, announced an agreement to acquire Chinook Therapeutics, a clinical-stage biotechnology company developing precision medicines for kidney diseases with an innovative medicine strategy and renal pipeline. Moreover, increasing product launches by key players is expected to drive growth of the market over the forecast period. For instance, on January 24, 2023, Boehringer Ingelheim International GmbH, a Germany-based global pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for phase III trial for Jardiance, which is being investigated to reduce the risk of kidney disease progression or cardiovascular death in adults with CKD.
Key features of the study:
- This report provides an in-depth analysis of the global hypertension in CKD market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hypertension in CKD market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBP Biosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypertension in CKD market
Global Hypertension in CKD Market Detailed Segmentation:
- By Drug Class:
- Diuretics
- RAS Blockade
- β-Blockers
- Calcium Channel Blockers
- Others (α-Blockers, Vasodilators, Proteinuria, etc.)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- Sanofi S.A
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
- KBP Biosciences Holdings Limited
- Ardelyx
- Reata Pharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd
- Pfizer Inc.
- Bayer Pharmaceuticals, Inc
- GSK plc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Key Developments
- Pipeline analysis
- Regulatory Scenario
- Key Developments
- Treatment Approaches
- PEST Analysis
4. Global Hypertension in CKD Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Hypertension in CKD Market, By Drug Class, 2018 - 030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- β-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Others (α-Blockers, Vasodilators, Proteinuria, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
6. Global Hypertension in CKD Market, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
7. Global Hypertension in CKD Market, By Region, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Sanofi S.A
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- KBP Biosciences Holdings Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Ardelyx
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Reata Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Kissei Pharmaceutical Co., Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer Pharmaceuticals, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GSK plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
9. Section
- References
- Research Methodology
- About us and Sales Contact
